Anti-EGFR enhanced neoadjuvant immunotherapy versus neoadjuvant immunochemotherapy for locally advanced oral squamous cell carcinoma.

ABSTRACT:

Background

Immune checkpoint inhibitors have transformed the management of metastatic oral squamous cell carcinoma (OSCC), but their efficacy in the neoadjuvant setting is still under investigation. This study aimed to compare the efficacy and safety of neoadjuvant immunochemotherapy (NAIC), neoadjuvant immunotherapy plus cetuximab (NAI-CTX), and neoadjuvant chemotherapy (NAC) in patients with locally advanced OSCC.

Methods

In this retrospective cohort study, 475 patients with stage III-IVA OSCC were stratified into three groups: NAIC (n=265), NAI-CTX (n=46), and NAC (n=164). The primary endpoint was pathologic complete response (pCR). Secondary endpoints included event-free survival (EFS), overall survival (OS), major pathologic response (mPR), and treatment-related toxicit

SUBMITTER: Li P 

PROVIDER: S-EPMC12675437 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature